Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE
Sponsor: German Cancer Research Center
A PHASE2 clinical study on Early-stage Breast Cancer, this trial is actively recruiting participants. The trial is conducted by German Cancer Research Center and has accumulated 8 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
8 versions recorded-
Apr 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE2
▶ Show 3 earlier versions
-
Mar 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE2
-
May 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- German Cancer Research Center
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Augsburg, Germany
- • Berlin, Germany
- • Dresden, Germany
- • Erlangen, Germany
- • Essen, Germany
- • Heidelberg, Germany
- • Tübingen, Germany
- • Ulm, Germany
- • Würzburg, Germany